Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 522 and 529 are amended as follows:

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 522.1662a [Amended]

2. Section 522.1662a *Oxytetracycline hydrochoride injection* is amended in paragraph (h)(2) by removing ''057319'' and adding in its place ''059130''.

PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 529 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 529.1044a [Amended]

4. Section 529.1044a *Gentamicin sulfate intrauterine solution* is amended in paragraph (b) by removing ''057319'' and adding in its place ''059130''.

Dated: January 28, 1998.

Andrew J. Beaulieau,

Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 98–3294 Filed 2–9–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558

New Animal Drugs For Use In Animal Feeds; Salinomycin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Hoffmann-La Roche, Inc. The NADA provides for use of an alternate formulation of salinomycin Type A medicated articles to make Type C medicated feeds.

EFFECTIVE DATE: February 10, 1998.

FOR FURTHER INFORMATION CONTACT: Mary G. Leadbetter, Center for Veterinary Medicine (HFV–143), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1662.

SUPPLEMENTARY INFORMATION: Hoffmann-La Roche, Inc., Nutley, NJ 07110–1199, is sponsor of NADA 128–686 that provides for use of Bio-Cox® (salinomycin) Type A medicated articles to make Type C medicated feeds for broiler, roaster, and replacement chickens, and quail. The firm filed a supplement to the NADA that provides for use of a 60-grams-per-pound (g/lb) salinomycin Type A medicated article in addition to the currently approved 30-g/lb product. The supplemental NADA is approved as of January 9, 1998, and the regulations are amended in 21 CFR 558.550(a)(1) to reflect the approval.

Approval of this supplemental NADA does not require additional safety or effectiveness data or information. A freedom of information summary as provided under 21 CFR part 20 and 514.11(e)(2)(ii) is not required.

The agency has determined under 21 CFR 25.33(a)(3) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in 21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under the authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

§ 558.550 [Amended]

2. Section 558.550 *Salinomycin* is amended in paragraph (a)(1) by removing ''30'' and adding in its place ''30 and 60''.

Dated: January 28, 1998.

Andrew J. Beaulieau,

Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 98–3293 Filed 2–9–98; 8:45 am]

BILLING CODE 4160–01–F

NATIONAL MEDIATION BOARD

29 CFR Part 1200

Repeal of Agency Promulgated Ethics Regulations

AGENCY: National Mediation Board.

ACTION: Final rule.

SUMMARY: The National Mediation Board (NMB) is repealing its regulations on the ethical conduct of employees. The repealed provisions are superseded by Office of Government Ethics (OGE) rules establishing uniform standards of conduct and financial disclosure requirements for executive branch employees.

DATES: This final rule is effective February 10, 1998.

FOR FURTHER INFORMATION CONTACT: Ronald M. Etters, General Counsel, National Mediation Board, 1301 K Street, NW, Washington, DC 20572, 202–523–5944. This is not a toll-free number.

SUPPLEMENTARY INFORMATION: In 1967 the National Mediation Board (NMB) issued Part 1200 (29 CFR Part 1200, 32 FR 15827, November 17, 1967), primarily pursuant to Executive Order 11222 (30 FR 6469) and regulations issued by the Civil Service Commission (5 CFR 735.104). Executive Order 12674 (April 12, 1989), as modified by Executive Order 12731 (October 7, 1990), revoked Executive Order 11222 (section 501(a)) and directed the Office of Government Ethics (OGE) to ''establish a single, comprehensive and clear set of executive-branch standards of conduct that shall be objective, reasonable and enforceable.'' (Section 201).

OGE issued 5 CFR Part 2635, Standards of Ethical Conduct for Employees of the Executive Branch (57 FR 35006, August 7, 1992). These standards of conduct superseded agency regulations promulgated pursuant to 5 CFR Part 735. The NMB is removing Part 1200 by repealing all provisions of Subparts A through D which were superseded when OGE's regulations took effect (February 3, 1993).

The NMB has determined that publication of a proposed rule is unnecessary since Part 1200 is duplicative and superseded by OGE rules establishing uniform standards of conduct and financial disclosure regulations for executive branch employees.

List of Subjects in 29 CFR 1200

Conflict of interests.